Cyclosporine

Generic Name
Cyclosporine
Brand Names
Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
Drug Type
Small Molecule
Chemical Formula
C62H111N11O12
CAS Number
59865-13-3
Unique Ingredient Identifier
83HN0GTJ6D
Background

Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...

Indication

Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...

Associated Conditions
Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
Associated Therapies
-
Clinical Trials
Related News

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

First Posted Date
2022-03-31
Last Posted Date
2022-07-01
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
64
Registration Number
NCT05303727
Locations
🇨🇳

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment

First Posted Date
2022-03-24
Last Posted Date
2022-03-24
Lead Sponsor
Peking University Third Hospital
Target Recruit Count
89
Registration Number
NCT05294666
Locations
🇨🇳

Peking University Third Hospital, Beijing, Beijing, China

Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants

First Posted Date
2022-01-21
Last Posted Date
2023-04-04
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
61
Registration Number
NCT05202145
Locations
🇺🇸

Clinical Study Site, Tempe, Arizona, United States

A Feasibility Study to Evaluate the Tolerability of Oph1 Compared to Restasis in Healthy Volunteers

Early Phase 1
Completed
Conditions
Dry Eye Syndromes
Interventions
Drug: Oph1
Drug: Restasis
First Posted Date
2022-01-11
Last Posted Date
2024-04-05
Lead Sponsor
OphRx Ltd.
Target Recruit Count
20
Registration Number
NCT05184517
Locations
🇮🇱

Shaare Zedek Medical Center, Jerusalem, Israel

A Study in Healthy Adult Participants to Assess the Effects of Ciclosporin Administration on Rilematovir

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Rilematovir
Drug: Ciclosporin
First Posted Date
2021-12-13
Last Posted Date
2022-02-17
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
18
Registration Number
NCT05155007
Locations
🇧🇪

Clinical Pharmacology Unit, Merksem, Belgium

Ciclosporin Followed by Low-dose IL-2 in Patients with Recently Diagnosed Type 1 Diabetes

Phase 2
Recruiting
Conditions
Type 1 Diabetes
Interventions
Drug: Cyclosporin
Drug: ILT101
Drug: Placebo
First Posted Date
2021-12-10
Last Posted Date
2024-11-21
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
24
Registration Number
NCT05153070
Locations
🇫🇷

Lorenzon Roberta, Paris, France

Microvascular and Inflammatory Responses of 0.05 Cyclosporine Eye Drop (II) in Treatment of Dry Eye

First Posted Date
2021-11-23
Last Posted Date
2022-02-11
Lead Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Target Recruit Count
100
Registration Number
NCT05131152
Locations
🇨🇳

Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China

Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis

Not Applicable
Not yet recruiting
Conditions
Ulcerative Colitis
Interventions
Drug: Cyclosporine
Drug: Tofacitinib
First Posted Date
2021-11-08
Last Posted Date
2023-03-29
Lead Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Target Recruit Count
96
Registration Number
NCT05112263

A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

First Posted Date
2021-11-05
Last Posted Date
2021-11-05
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
72
Registration Number
NCT05109390
Locations
🇺🇸

Clinical Trial Site, Tempe, Arizona, United States

Second-line Treatment of Primary Autoimmune Hemolytic Anemia

First Posted Date
2021-09-27
Last Posted Date
2021-10-22
Lead Sponsor
Assiut University
Target Recruit Count
30
Registration Number
NCT05057468
Locations
🇪🇬

Assiut university hospital, Assiut, Egypt

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy